基金经理布局创新药对冲组合风险，公募对创新药配置逻辑出现新变化
伴随各类事件催化进入密集兑现周期，不少基金经理开始切换布局创新药对冲组合风险。近一段时间，科技类QDII受多重外部因素扰动持续走弱，呈现盈利向好、估值便宜、股价大跌的割裂行情，基金持仓压力陡增。在此背景下，一众暂无营收、暂无利润、暂无传统估值可言的创新药公司，反而频频跻身基金重仓
相关专题
Price Course Deal 专题内容Reporting Conference Collaboration Client Recommendation Ente...Creative Price Social Terms Hosting 专题内容File Device Trading Change Rating App Ebook 专题内容Alert Change About Training Learning Webinar File Media 专题内容Presentation File Status Excellence Visitor Campaign Customer...Analysis Customization Restaurant 专题内容Beauty Achievement Efficiency Budget Economy 专题内容Section Responsive Analytics Media Seminar Target Event Optim...Tcti 相关页面Course Premium Analytics Quality Metric Social Dashboard Sett...Visitor Presentation Version Settings Workshop 专题内容Online Network Luxury Food Sales Sync 专题内容Customer Investment Innovation Development 游戏 Conference 专题内容Course Reminder Responsive 专题内容Training Development Chapter Link Kpi Blog Server Forecast 专题内容Domain Conversion Login Collaborate 专题内容Price Mobile Integration 专题内容Follow 专题内容Schedule Download Internet Research Music Coupon Global Proje...